The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue SUPPL. 36, 1997, Pages 33-40

  Meltzer, E O ^a  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

Cytokines; Fluticasone propionate; Inflammation; Pharmacology; Rhinitis; Topical corticosteroids

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHEMOKINE; CORTICOSTEROID; CYTOKINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HISTAMINE AGONIST; HYDROCORTISONE; LEUKOTRIENE; PLACEBO; PROSTANOID; TETRACOSACTIDE; TRIAMCINOLONE ACETONIDE; TRYPTASE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPISTAXIS; HUMAN; INTRANASAL DRUG ADMINISTRATION; PERENNIAL RHINITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; BASOPHILS; BLOOD VESSELS; CLINICAL TRIALS; EOSINOPHILS; EPITHELIAL CELLS; EPITHELIUM; HUMANS; MACROPHAGES; MAST CELLS; NEUTROPHILS; RHINITIS; RHINITIS, ALLERGIC, PERENNIAL; T-LYMPHOCYTES;

EID: 0030762588     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb04820.x     Document Type: Conference Paper

References (65)

1. Durham SR, Gould HJ, Thienes CP et al. Local control of e-gene expression in B cells of the nasal mucosa in hay fever patients following allergen challenge [Abstract]. J Allergy Clin Immunol 1996;97:297.
2. Sims TC, Reece LM, Hilsmeier KA et al. Secretions of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995;152:927-33.
3. Rak S, Jacobson MR, Sudderick RM et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994;24:930-9.
4. Cohen JJ. Lymphocyte death induced by glucocorticoids. In: Schleimer RP, Claman HN, Oronsky A, editors. Antiinflammatory steroid action: basic and clinical aspects. San Diego: Academic Press, 1989:110-31.
5. Masuyama K, Jacobson MR, Rak S et al. Topical gluco-corticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994;82:192-9.
6. Alvarado C, Reed C, Gleich G et al. Fluticasone propionate aqueous nasal spray reduces nasal eosinophils and cytokine activity of patients with allergic rhinitis [Abstract]. J Allergy Clin Immunol 1995;95:193.
7. Schleimer RP. Glucocorticosteroids: their mechanism of action and use in allergic diseases. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, editors. Allergy principles and practice. 3rd edition. Washington, DC: Mosby 1988:739-65.
8. Reed JC, Abidi AH, Alpers JD et al. Effect of cyclosporin A and dexamethasone on interleukin-2 receptor gene expression. J Immunol 1986;137:150-4.
9. Wardlaw AJ, Moqbel R, Kay AB. Eosinophils: biology and role in disease. Adv Immunol 1995;60:151.
10. 4 by human eosinophils. J Immunol 1987;138:532.
11. Zoratti EM, Sedgwick JB, Vrtiš RR, Busse WW. The effect of platelet activating factor on the generation of superoxide anion in human eosinophils and neutrophils. J Allergy Clin Immunol 1991;88:749.
12. Her E, Frazer J, Austen KF, Owen WF. Eosinophil hemato-poietins. antagonize the programmed cell death of eosinophils: cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell conditioned medium. J Clin Invest 1992;88:1982.
13. Schleimer RP. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990;141:S59-69.
14. Bochner BS, Schleimer RP. Endothelial cells and cell adhesion. In: Kaplan AP, editor. Allergy. 2nd edition. Orlando: WB Saunders (in press).
15. Staruch MJ, Wood DD. Reduction of serum interleukin-1-like activity after treatment with dexamethasone. J Leukoc Biol 1985;37:193-207.
16. Beck L, Bickel C, Sterbinsky S et al. Injection of human subjects with RANTES causes dermal infiltration of eosinophils (EOS) and mononuclear cells (MNC) [Abstract], FASEB J 1995;9:A804.
17. Stellato C, Beck LA, Gorgone GA et al. Expression of the chemokine RANTES by a human bronchial epithelial cell line: modulation by cytokines and glucocorticoids. J Immunol 1995;155:410-8.
18. Warringa RAJ, Loenderman L, Kok PTM et al. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Blood 1991;77:2694-700.
19. Kato M, Schleimer RP. Antiinflammatory steroids inhibit GM-CSF production by human lung tissue. Lung 1994; 172:113-24.
20. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
21. van As A, Bronsky EA, Dockhom RJ et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146-54.
22. Igarashi Y, Kaliner MA, Hausfeld JN et al. Quantification of resident inflammatory cells in the human nasal mucosa. J Allergy Clin Immunol 1993;91:1082-93.
23. Gomez E, Corrado OJ, Baldwin DL et al. Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in man. J Allergy Clin Immunol 1986; 78:637-45.
24. Naclerio RM, Proud D, Togias AG et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313:65-70.
25. Castells M, Schwartz LB. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol 1988;82:348-55.
26. Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of the cytokines. Am J Respir Cell Mol Biol 1994;10:471-80.
27. Dahl R, Johansson SA. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis 1982;122(Suppl.): 167-75.
28. Schleimer RP. The effects of anti-inflammatory steroids on mast cells. In: Kaliner M, Metcalfe D, editors. The mast cell in health and disease. New York: Marcel Dekker, 1992:483.
29. Gomez E, Claque JE, Gatland D, Davis RJ. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells. Br Med J 1988;296:1572-3.
30. Bascom R, Wachs M, Naclerio RM et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988; 81:580.
31. Blackwell GJ, Canniccio R, Di Rossa M et al. Macrocortin: a polypeptide causing the antiphospholipase effect of glucocorticoids. Nature 1980;287:147-9.
32. Pipkorn U, Proud D, Lichtenstein LM et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987;316:1506.
33. Schleimer RP, Lichtenstein LM, Gillespie E. Inhibition of basophil histamine release by antiinflammatory steroids. Nature 1981;292:454-5.
34. Meltzer EO, Jalowayski AA, Field EA et al. Intranasal fluticasone propionate reduces histamine and tryptase in the mucosa of allergic rhinitis patients [Abstract]. J Allergy Clin Immunol 1993;91:298.
35. Schweibert LA, Beck LA, Stellato C et al. Glucocorticoid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996;97:143-52.
36. Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Am Rev Respir Dis 1988;138:406-12.
37. Bochner B, Rutledge BK, Schleimer RP. Interleukin-1 production by human lung tissue. II. Inhibition by antiinflammatory steroids. J Immunol 1987;39:2303.
38. Fuller RW, Morris PK, Sykes RD et al. Immunoglobulin E-dependent stimulation in human alveolar macrophages: significance in type 1 hypersensitivity. Clin Exp Immunol 1986;65:416-26.
39. Guyre PM, Munck A. Glucocorticoid action on monocytes and macrophages. In: Schleimer RP, Claman HN, Oronsky AR, editors. Antiinflammatory steroid action. Basic and clinical aspects. New York: Academic Press, 1991: 199-225.
40. Kamada AK, Szefler SJ. Mechanisms of action of glucocorticoids in asthma and rhinitis. In: Busse WW, Holgate ST, editors. Asthma and rhinitis. Boston: Blackwell Scientific Publications, 1995:1255-66.
41. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979;278:456-9.
42. Hirata F, Notsu Y, Iwata M et al. Identification of several species of phospholipase inhibitory protein(s) by radioimmunoassay for lipomodulin. Biochem Biophys Res Commun 1982;109:223-30.
43. Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1983;1:335.
44. Martin S, Maruta K, Burkart V et al. IL-1 and IFN-gamma increase vascular permeability. Immunology 1988;64:301.
45. Flower RJ. Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol 1988;94:987-1015.
46. Williams TJ, Yarwood H. Effect of glucocorticosteroids on microvascular permeability. Am Rev Respir Dis 1990; 141:S39.
47. Boschetto P, Rogers DF, Fabbri LM et al. Corticosteroid inhibition of microvascular leakage. Am Rev Respir Dis 1991;143:605.
48. Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991;88:147-55.
49. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. In: Barnes PJ, editor. New drugs for asthma. Volume 2. London: IBC Technical Services, 1992:193-208.
50. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-75.
51. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
52. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148(Suppl.):S1-26.
53. English AF, Neate MS, Quint DJ, Sareen M. Biologic activities of some corticosteroids used in asthma [Abstract]. Am J Respir Crit Care Med 1994;149:A212.
54. Brattsand R, Thalen A, Roempke K et al. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982; 122(Suppl.):62-73.
55. Hampel F, Howland W, Martin B et al. The efficacy of fluticasone propionate aqueous nasal spray for treatment of rhinitis is dependent on topical application [Abstract]. J Allergy Clin Immunol 1994;93:165.
56. Wachs M, Proud D, Lichtenstein LM et al. Nasal printing. J Allergy Clin Immunol 1987;79:253.
57. Naclerio RM, Meier HC, Adkinson NF et al. In vivo demonstration of inflammatory mediator release following nasal challenge with antigen. Eur J Respir Dis 1983; 64(Suppl.):26.
58. Andersson M, Andersson P, Pipkorn U. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity: relationship between treatment time and inhibitory effect. J Allergy Clin Immunol 1988;82:1919.
59. Veld CD, Garrelds IM, Jansen APH et al. Effect of intranasal fluticasone propionate on the immediate and late allergic reaction and nasal hyperreactivity in patients with a house dust mite allergy. Clin Exp Allergy 1995; 25:966-73.
60. Banov CH, Woehler TR, LaForce CF et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994;73:240-6.
61. Seiner J, Banov C, Boltansky H et al. Fluticasone propionate aqueous nasal spray effectively treats perennial non-allergic rhinitis [Abstract]. J Allergy Clin Immunol 1994;93:165.
62. Brannon MD, Herrón JM, Reidenberg P, Affrime MB. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipro-pionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 1995;17:637-47.
63. Vargas R, McMahon FG, Dockhorn R et al. An assessment of HPA axis effects of fluticasone propionate aqueous nasal spray using 6-hour ACTH infusion [Abstract]. Clin Pharm Ther 1994;55:184.
64. McCubbin MM, Milavetz G, Grandgeorge S et al. A bio-assay for topical and systemic effect of three inhaled corticosteroids. Clin Pharmacol Ther 1995;57: 455-60.
65. Li J, Lyles K, Halstenson C et al. Long-term safety study of fluticasone propionate aqueous nasal spray [Abstract]. Ann Allergy 1995;74:58.